Celltrion said Oct. 24 it will participate in CPHI Worldwide 2025 in Frankfurt from Oct. 28–30 (local time), using the global pharmaceutical ingredients event to broaden international partnerships.
Now in its 36th year, CPHI is one of the world’s largest pharma and biotech exhibitions, drawing industry professionals from more than 170 countries and roughly 60,000 attendees. Celltrion has maintained a solo booth on the show floor annually since 2022 to strengthen global partnerships and raise brand awareness.
This year the company will host a large standalone booth of about 202 square meters on a main aisle, featuring private and open meeting spaces and an expanded footprint compared with last year to facilitate partner meetings. Celltrion plans on-site promotion with visitor giveaways and interactive events at the booth.
The company said it will emphasize reinforcing networks with existing suppliers and contract manufacturing (CMO) partners while accelerating efforts to secure new partners to stabilize supply chains amid rising production demand driven by its expanding product lineup. Recent global launches include biosimilars for autoimmune diseases—Stekima (ustekinumab) and Aptozma (tocilizumab)—bone disease treatment Stovoclo-Osenbelt (denosumab) and dermatology drug Omriclo (omalizumab), which have broadened Celltrion’s commercial portfolio.
Celltrion also intends to explore collaboration opportunities in new modality-based businesses and automation process technologies, aiming to stay abreast of industry trends and identify potential partners with core capabilities to pursue new market opportunities.
A Celltrion spokesperson said the company will use CPHI to promote its brand and technology competitiveness, expand cooperation with promising global firms, strengthen production infrastructure for its larger product portfolio and pursue strategic partnerships in future growth areas to reinforce its global position.
